1234345-57-3

Upstream product

• 134841-10-4 (2E)-3-[(3-acetyloxy)-4-methoxyphenyl]acrylic acid 

Downstream Products

• 1451180-84-9 (R,E)-2-(4-(5-(1,2-dithiolan-3-yl)pentanoyl)piperazin-1-yl)ethyl 3-(3-acetoxy-4-methoxyphenyl)acrylate 
• 1613391-39-1 (E)-3-(3-acetoxy-4-methoxyphenyl)-N-(2-naphthyl)-prop-2-enamide 
• 1223569-56-9 (E)-3-(3-acetoxy-4-methoxyphenyl)-N-(1-methyl-1H-benzimidazol-2-yl)prop-2-enamide 
• 1613391-41-5 (E)-N-(3-chlorophenyl)-3-(3-acetoxy-4-methoxyphenyl)-N-methyl-prop-2-enamide 
• 1223569-58-1 (E)-N-benzoxazol-4-yl-3-(3-acetoxy-4-methoxyphenyl)prop-2-enamide 
• 1613391-40-4 C₂₀H₁₉N₃O₄ 
• 1223569-25-2 (E)-3-(3-acetoxy-4-methoxyphenyl)-N-(1-naphthyl)prop-2-enamide 
• 1613391-38-0 (E)-N-(3-carboxamidophenyl)-3-(3-acetoxy-4-methoxyphenyl)prop-2-enamide 
• 1613391-23-3 (E)-N-(3-carboxamidophenyl)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enamide 
• 1223568-46-4 (E)-3-(3-hydroxy-4-methoxyphenyl)-N-indan-1-yl-acrylamide 
• 1613391-24-4 (E)-3-(3-hydroxy-4-methoxy-phenyl)-N-(2-naphthyl)-prop-2-enamide 
• 1223568-23-7 (E)-N-(3,4-dichlorophenyl)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enamide 
• 1223568-24-8 (E)-N-(3-chloro-4-methoxyphenyl)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enamide 
• 1223568-21-5 (E)-N-(3-chloro-2-methoxyphenyl)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enamide 

Relevant academic research and scientific papers

Imidazolylamide derivative

The present invention pertains to an imidazolylamide derivative represented by formula (1) that exhibits an exceptional suppressive effect on cancer cell sphere formation ability and that is useful as an antitumor agent that can be administered orally, or a pharmacologically acceptable salt thereof. [In the formula, ring Q1 represents a C6-10 aryl group or the like; m represents 0, 1, 2, 3, 4, or 5; R3, independently when multiple, represent(s) a halogen atom or the like; R1 and R2 independently represent a hydrogen atom or the like; W1 represents a C1-4 alkylene group (said group may be substituted by 1-3 fluorine atoms or C3-7 cycloalkyls); W2 represents —NR4aC(O)— or the like (where R4a represents a hydrogen atom or C1-6 alkyl group); and ring Q2 represents a C6-10 arylgroup or the like]

Design and synthesis novel di-carbonyl analogs of curcumin (DACs) act as potent anti-inflammatory agents against LPS-induced acute lung injury (ALI)

A novel series of di-carbonyl analogs of curcumin (DACs) were prepared and evaluated for their anti-inflammatory properties. Preliminary results showed that a vast majority of compounds tested in this study could effectively suppress LPS-induced production of tumor necrosis factor (TNF)-α and interleukin (IL)-6. Structure-activity relationships of the compounds were discussed. Compounds 5a27 and 5a28 showed the most potent anti-inflammatory activities and had higher structural stability and orally bioavailability than curcumin in vitro. Mechanistically, they inhibited the activation of macrophages via the blockade of mitogen-activated protein kinase (MAPK) signaling and nuclear translocation of NF-κB. In vivo, 5a27 and 5a28 markedly alleviated lipopolysaccharides (LPS)-induced acute lung injury (ALI). The wet/dry ratio of lungs was significantly normalized by the active compounds, which was consistent with the suppression of neutrophil infiltration and production of proinflammatory cytokines. Collectively, these results present a new series of curcumin analogs as promising anti-inflammatory agents for treatment of ALI.

Synthesis and anticancer activity evaluation of some new derivatives of 2-(4-benzoyl-1-piperazinyl)-quinoline and 2-(4-cinnamoyl-1-piperazinyl)-quinoline

In this study, we designed and synthesized twenty new derivatives of 2-(4-benzoyl-1-piperazinyl)- quinoline and 2-(4-cinnamoyl-1-piperazinyl)-quinoline with potential anticancer activity. The structures of synthesized compounds were confirmed by 1H and 13C NMR spectroscopy and MS spectrometry. The activity of novel compounds was evaluated in the cell viability assay as well as in the wound healing assay. Presented data show that examined substances have anticancer activity in cell culture. Seven compounds which showed a high rate of cell growth inhibition were selected for further studies. Three of them strongly reduced the growth of B16F10 cells. The novel compounds constitute a good base for further studies and optimization of structure for new therapeutically effective anti-cancerous drugs.

Cinnamic anilides as new mitochondrial permeability transition pore inhibitors endowed with ischemia-reperfusion injury protective effect in vivo

In this account, we report the development of a series of substituted cinnamic anilides that represents a novel class of mitochondrial permeability transition pore (mPTP) inhibitors. Initial class expansion led to the establishment of the basic structural requirements for activity and to the identification of derivatives with inhibitory potency higher than that of the standard inhibitor cyclosporine-A (CsA). These compounds can inhibit mPTP opening in response to several stimuli including calcium overload, oxidative stress, and thiol cross-linkers. The activity of the cinnamic anilide mPTP inhibitors turned out to be additive with that of CsA, suggesting for these inhibitors a molecular target different from cyclophylin-D. In vitro and in vivo data are presented for (E)-3-(4-fluoro-3-hydroxy-phenyl)-N-naphthalen-1-yl- acrylamide 22, one of the most interesting compounds in this series, able to attenuate opening of the mPTP and limit reperfusion injury in a rabbit model of acute myocardial infarction.